Aldosterone impairs vascular endothelial cell function

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 4, 2006, Pages 609-613

  Hashikabe, Yuko ^a   Suzuki, Kunihiro ^a   Jojima, Teruo ^a   Uchida, Kohsuke ^a   Hattori, Yoshiyuki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Endothelial dysfunction; NADPH oxidase; NF B; NO

Indexed keywords

ALDOSTERONE; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; I KAPPA B KINASE GAMMA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; PROTEIN NOX4; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ALDOSTERONE; BLOTTING, WESTERN; CELLS, CULTURED; CHEMOKINE CCL2; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; NADPH OXIDASE; NF-KAPPA B; NITRIC OXIDE; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 33748170993     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211738.63207.c3     Document Type: Article

References (19)

1. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
2. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A. Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA. 1998;95:2973-2978.
3. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
4. Duprez D, De Buyzere M, Rietzschel ER, et al. Aldosterone and vascular damage. Curr Hypertens Rep. 2000;2:327-334.
5. Stier CT Jr., Chander PN, Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 2002;10:97-107.
6. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 2004;287:H435-H446.
7. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone, Circulation. 2004;109:2213-2220.
8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
9. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
10. Keida Sr, Hayek T, Kaplan M, et al. Aviram, Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955-963.
11. Sorescu D, Weiss D, Lassegue B, et al. Griendling, Superoxide production and expression of Nox family proteins in human atherosclerosis. Circulation. 2002;105:1429-1435.
12. Hattori Y, Hattori S, Kasai K. Globular adiponectin activates NF-κB in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care. 2006;29:139-141.
13. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999;99:2027-2033.
14. Laursen JB, Somers M, Kurz S. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288.
15. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun. 1999;263:681-684.
16. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
17. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-21103.
18. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
19. Cooke CM, Davidge ST. Peroxynitrite increases iNOS through NF-κB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol. 2002;282:C395-C402.